This proposed study will examine feasibility and implement therapeutic bright light that is tailored to the individual's circadian typology to estimate its therapeutic effects on sleep/wake patterns and fatigue in breast cancer patients undergoing chemotherapy.
21 years of age or older Newly diagnosed with stage I-III breast cancer Scheduled to receive 21-day cycles of intravenous chemotherapy Experiencing disrupted sleep (determined by Pittsburgh Sleep Quality Index) Morning or evening types (determined by Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ) Sighted Mentally competent to consent Able to under English
Exclusion Criteria:
Concurrent malignancy Undergoing other cancer treatments Engage in shift work or travel across more than 3 time zones within 2 weeks prior to study Known history of seasonal affective disorder or substance abuse Current diagnosis of major Axis I psychiatric disorders, neurological impairments, or muscular dystrophies Regularly use steroid or other immunosuppressive medications Take prescribed sedative hypnotics or sleep medications because these conditions may affect fatigue and/or sleep/wake patterns. Have eye conditions (glaucoma or retinal disease), problems triggered by bright light (e.g. migraine), or take photosensitizing medications (e.g. some porphyrin drugs, antipsychotics, antiarrhythmic agents)
